Key Takeaways:
- Dr. Louis Teulières, a multi-national doctor with an MD and PhD, has been actively involved with ILADS since 2016 due to his research on bacteriophages at the University of Leicester.
- Frustrated with the limitations of antibiotic treatments for Borrelia, the bacteria that causes Lyme disease, Dr. Teulières explored bacteriophages as a novel diagnostic and therapeutic approach.
- Due to regulatory challenges in administering phage therapy, Dr. Teulières and his team developed a phage-based test that can directly detect the presence of Borrelia bacteria.
- This test, marketed by Red Labs in Europe for the past four years, has been used on thousands of patients and can differentiate between early, late-stage, and post-treatment Lyme disease.
- Dr. Teulières is now working to expand the test’s reach in the U.S., seeking partnerships with American clinicians and researchers to validate the test and pursue FDA clearance.
- The discussion underscores the need for innovative diagnostic tools to improve Lyme disease detection and accelerate healing journeys for patients.
About Dr. Louis Teulières:
- Medical degree from University of Nice, France.
- Specializations in immunology, hematology, immunopathology, bacteriology, and epidemiology at the Pasteur Institute in Paris and CDC in Atlanta.
- Former researcher at the Pasteur Institute, contributing to studies on immune and infectious diseases such as HIV.
- Active member of the immunology team that received the Nobel Prize in 2008 for discovering the HIV virus in 1983.
- Founder of CMIL clinics in Lisbon and Paris, specializing in immune and infectious diseases, Lyme disease, and neurodegenerative conditions.
- Co-founder of PHELIX, a charity dedicated to phage-based research and diagnostics in Lyme disease.
- Collaborates with University of Leicester, St Thomas Hospital in London, and other world-class healthcare professionals.
Resources & Links:
